Skip to main content
PMC home page
Archives of Disease in Childhood. Fetal and Neonatal Edition logoLink to Archives of Disease in Childhood. Fetal and Neonatal Edition
. 1997 Nov;77(3):F241–F243. doi: 10.1136/fn.77.3.f241

Effects of cisapride on QTc interval in neonates

S Bernardini, D Semama, F Huet, C Sgro, J Gouyon
PMCID: PMC1720707  PMID: 9462199

Abstract

AIM—Prospective survey of the effects of cisapride on QTc interval in neonates given cisapride.
METHODS—QTc interval was determined just before and 2.9 (0.9) days after outset of the treatment in 49 neonates treated with cisapride between 1 August 1995 and 29 February 1996.
RESULTS—Cisapride significantly increased QTc interval (p = 0.0001), and this was higher when birthweight or gestational age were lower. The prolongation of QTc interval above the arbitrary value of 0.450 (n = 7) was clinically asymptomatic and was significantly more common in the infants born with a gestational age ⩽ 33 weeks (n = 6).
CONCLUSION—The findings indicate that cisapride accumulates in less mature neonates. Further pharmacokinetic studies are needed.

 Keywords: cisapride; QT interval; QTc interval

Full Text

The Full Text of this article is available as a PDF (126.5 KB).

Figure 1  .

Figure 1  

Open in a new tab

Distribution of neonates enrolled in the survey according to gestational age: □ patients with QTc interval above 0.450 after treatment with cisapride; ▪ patients with no QTc interval increase above 0.450 after treatment with cisapride.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boehm G., Teichmann B., Krumbiegel P. Hepatic biotransformation capacity in low-birth-weight infants as measured with the [15N]methacetin urine test: influences of gestational age, postnatal age, and intrauterine growth retardation. Biol Neonate. 1995;68(1):19–25. doi: 10.1159/000244213. [DOI] [PubMed] [Google Scholar]
  2. Bran S., Murray W. A., Hirsch I. B., Palmer J. P. Long QT syndrome during high-dose cisapride. Arch Intern Med. 1995 Apr 10;155(7):765–768. [PubMed] [Google Scholar]
  3. Ervine C. M., Matthew D. E., Brennan B., Houston J. B. Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. Drug Metab Dispos. 1996 Feb;24(2):211–215. [PubMed] [Google Scholar]
  4. Greenblatt D. J., von Moltke L. L., Harmatz J. S., Harrel L. M., Tobias S., Shader R. I., Wright C. E. Interaction of triazolam and ketoconazole. Lancet. 1995 Jan 21;345(8943):191–191. doi: 10.1016/s0140-6736(95)90193-0. [DOI] [PubMed] [Google Scholar]
  5. Janssens G., Melis K., Vaerenberg M. Long-term use of cisapride (prepulsid) in premature neonates of less than 34 weeks gestational age. J Pediatr Gastroenterol Nutr. 1990 Oct;11(3):420–422. [PubMed] [Google Scholar]
  6. Lewin M. B., Bryant R. M., Fenrich A. L., Grifka R. G. Cisapride-induced long QT interval. J Pediatr. 1996 Feb;128(2):279–281. doi: 10.1016/s0022-3476(96)70409-2. [DOI] [PubMed] [Google Scholar]
  7. Melis K., Janssens G. Long-term use of cisapride (Prepulsid) in premature neonates. Acta Gastroenterol Belg. 1990 Jul-Aug;53(4):372–375. [PubMed] [Google Scholar]
  8. Olsson S., Edwards I. R. Tachycardia during cisapride treatment. BMJ. 1992 Sep 26;305(6856):748–749. doi: 10.1136/bmj.305.6856.748-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Puisieux F. L., Adamantidis M. M., Dumotier B. M., Dupuis B. A. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol. 1996 Apr;117(7):1377–1379. doi: 10.1111/j.1476-5381.1996.tb15295.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rogers A. S. The role of cytochrome P450 in developmental pharmacology. J Adolesc Health. 1994 Dec;15(8):635–640. doi: 10.1016/s1054-139x(94)90630-0. [DOI] [PubMed] [Google Scholar]
  11. Schwartz P. J., Montemerlo M., Facchini M., Salice P., Rosti D., Poggio G., Giorgetti R. The QT interval throughout the first 6 months of life: a prospective study. Circulation. 1982 Sep;66(3):496–501. doi: 10.1161/01.cir.66.3.496. [DOI] [PubMed] [Google Scholar]
  12. Tan H. L., Hou C. J., Lauer M. R., Sung R. J. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med. 1995 May 1;122(9):701–714. doi: 10.7326/0003-4819-122-9-199505010-00009. [DOI] [PubMed] [Google Scholar]
  13. Wiseman L. R., Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs. 1994 Jan;47(1):116–152. doi: 10.2165/00003495-199447010-00008. [DOI] [PubMed] [Google Scholar]
  14. Wysowski D. K., Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 1996 Jul 25;335(4):290–291. doi: 10.1056/NEJM199607253350416. [DOI] [PubMed] [Google Scholar]
  15. Zehender M., Hohnloser S., Just H. QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drugs Ther. 1991 Apr;5(2):515–530. doi: 10.1007/BF03029779. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood Fetal and Neonatal Edition are provided here courtesy of BMJ Publishing Group

RESOURCES